Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 GILD | Healthcare | $168.08 | 3.64M | $208.31B | -54.22 | 1.93% | Strong Buy |
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| GILD | Gilead Sciences | 168.08 | 46.08 | 37.77% |
| Name | Price | % Change | |
|---|---|---|---|
| GILD | $168.08 | +37.77% |
As previously reported, Evercore ISI downgraded Legend Biotech (LEGN) to In Line from Outperform with a $20 price target following a transfer in analyst coverage. The firm says that while
Argus raised the firm’s price target on Gilead (GILD) to $190 from $165 and keeps a Buy rating on the shares. The stock has risen to new all-time highs following
Gilead (GILD) Sciences announced a new collaboration with TelevisaUnivision and the 27th Latin GRAMMY Awards that will bring HIV prevention awareness into one of the most prominent cultural moments for
Maxim Group analyst Michael Okunewitch has maintained their bullish stance on GILD stock, giving a Buy rating yesterday. Michael Okunewitch gave his Buy rating based on several factors, including Gilead’s
Gilead (GILD) Sciences announced results from the PURPOSE 5 trial showing significantly higher persistence-defined as consistent and continuous on-time use-among people starting twice-yearly injectable lenacapavir for HIV prevention as pre-exposure
Gilead (GILD) Sciences announced the detailed results from the Phase 3 IDEAL study, which demonstrated that the majority of participants living with PBC and treated with Livdelzi achieved the alkaline
Gilead Sciences ($GILD) announced an update on their ongoing clinical study. Study Overview: Gilead Sciences is studying GS-1206 in adults with solid tumors under the official title, “A Phase 1
Gilead (GILD) Sciences and Kite, a Gilead Company announced 23 presentations, including 7 oral presentations, will be presented at the 68th American Society of Hematology, ASH, Annual Meeting and Exposition.
Eli Lilly ($LLY), UnitedHealth ($UNH), and Gilead Sciences ($GILD) are three healthcare stocks with Strong Buy analyst ratings. All three stocks also have a Perfect 10 Smart Score on TipRanks.
Gilead (GILD) Sciences announced its upcoming participation in the International Congress on Drug Therapy in HIV Infection, taking place from November 8-11. Results from more than 50 studies, including late-breaking
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| GILD | buy | Reiterated | Nov 11, 2026 | |||
| GILD | buy | Reiterated | Nov 10, 2026 | |||
| GILD | hold | Reiterated | Nov 5, 2026 | |||
| GILD | buy | Reiterated | Nov 5, 2026 | |||
| GILD | buy | Reiterated | Nov 4, 2026 | |||
| GILD | buy | Reiterated | Nov 2, 2026 | |||
| GILD | hold | Reiterated | Nov 2, 2026 | |||
| GILD | buy | Reiterated | Oct 30, 2026 | |||
| GILD | buy | Reiterated | Oct 30, 2026 | |||
| GILD | buy | Reiterated | Oct 30, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| GILD | Feb 4, 2027TBA | $208.31B | $1.29 | $8.30B | 0.01 | -54.22 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
